Naoto Takahashi

ResearcherID Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 34

Top Topics

Helicobacter Pylori Infection

Newly Diagnosed

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

International journal of hematology

Journal of clinical pharmacy and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Yoshihiro Kameoka, Satoshi Kimura, Noriyasu Fukushima, Tatsuo Ichinohe, Ayako Takamori, Atsushi Kawaguchi, Masatomo Miura, Shinya Kimura
A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial). International journal of hematology (2024)
Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. Blood advances (2024)
Hidenori Wada, Ryo Yanagiya, Yuji Miyatake, Joaquim Carreras, Hiroshi Higuchi, Hiromichi Murayama, Takashi Ishida, Asahi Ito, Shinsuke Iida, Noriko Fukuhara, Hideo Harigae, Yuki Fujioka, Naoto Takahashi, Hidenori Wada, Fumihiro Ishida, Hideyuki Nakazawa, Rei Ishihara, Yuki Murakami, Hiroyuki Tagawa, Tadashi Matsuura, So Nakagawa, Sadahiro Iwabuchi, Shinichi Hashimoto, Ken-Ichi Imadome, Naoya Nakamura, Kenichi Ishizawa, Yoshinobu Kanda, Kiyoshi Ando, Ai Kotani
Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis. Blood (2023)
Ko Abe, Sho Ikeda, Miho Nara, Akihiro Kitadate, Hiroyuki Tagawa, Naoto Takahashi
Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. Cancer medicine (2023)
Hidenori Wada, Ryo Yanagiya, Yuji Miyatake, Joaquim Carreras, Hiroshi Higuchi, Hiromichi Murayama, Takashi Ishida, Asahi Ito, Shinsuke Iida, Noriko Fukuhara, Hideo Harigae, Yuki Fujioka, Naoto Takahashi, Hidenori Wada, Fumihiro Ishida, Hideyuki Nakazawa, Rei Ishihara, Yuki Murakami, Hiroyuki Tagawa, Tadashi Matsuura, So Nakagawa, Sadahiro Iwabuchi, Shinichi Hashimoto, Ken-Ichi Imadome, Naoya Nakamura, Kenichi Ishizawa, Yoshinobu Kanda, Kiyoshi Ando, Ai Kotani
Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis. Blood (2023)
Naoko Hosono, Sung-Gi Chi, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Kensuke Usuki, Yoshikazu Utsu, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Satoshi Iyama, Kensuke Kojima, Yukinori Nakamura, Suguru Fukuhara, Koji Izutsu, Hikaru Abutani, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami, null null
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer science (2023)
Naoko Hosono, Sung-Gi Chi, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Kensuke Usuki, Yoshikazu Utsu, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Satoshi Iyama, Kensuke Kojima, Yukinori Nakamura, Suguru Fukuhara, Koji Izutsu, Hikaru Abutani, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami, null null
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer science (2023)
Jiro Kikuchi, Nobuyuki Kodama, Masataka Takeshita, Sho Ikeda, Takahiro Kobayashi, Yoshiaki Kuroda, Michihiro Uchiyama, Naoki Osada, Bjarne Bogen, Hiroshi Yasui, Naoto Takahashi, Akiyoshi Miwa, Yusuke Furukawa
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood advances (2022)
Naoto Takahashi, Yoshihiro Kameoka, Makoto Onizuka, Yasushi Onishi, Fumiaki Takahashi, Takashi Dan, Toshio Miyata, Kiyoshi Ando, Hideo Harigae
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer medicine (2022)
Naoto Takahashi, Jorge E Cortes, Emiko Sakaida, Kenichi Ishizawa, Takaaki Ono, Noriko Doki, Itaru Matsumura, Valentín García-Gutiérrez, Gianantonio Rosti, Chiho Ono, Masayuki Ohkura, Yusuke Tanetsugu, Andrea Viqueira, Tim H Brümmendorf
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. International journal of hematology 115 (6) (2022)
Yuka Matsuda, Sho Ikeda, Fumito Abe, Yuto Takahashi, Akihiro Kitadate, Naoto Takahashi, Hideki Wakui, Hiroyuki Tagawa
Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma. Cancer science 113 (4) (2022)
Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML. Cancer science (2022)
Kunio Hayashi, Kazuhiro Ikegame, Naoto Takahashi
The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment. Case reports in hematology 2021 (2021)
Yotaro Ochi, Kenichi Yoshida, Ying-Jung Huang, Ming-Chung Kuo, Yasuhito Nannya, Ko Sasaki, Kinuko Mitani, Noriko Hosoya, Nobuhiro Hiramoto, Takayuki Ishikawa, Susan Branford, Naranie Shanmuganathan, Kazuma Ohyashiki, Naoto Takahashi, Tomoiku Takaku, Shun Tsuchiya, Nobuhiro Kanemura, Nobuhiko Nakamura, Yasunori Ueda, Satoshi Yoshihara, Rabindranath Bera, Yusuke Shiozawa, Lanying Zhao, June Takeda, Yosaku Watatani, Rurika Okuda, Hideki Makishima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Akifumi Takaori-Kondo, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nature communications 12 (1) (2021)
Akihiro Kitadate, Toshiki Terao, Kentaro Narita, Sho Ikeda, Yuto Takahashi, Takafumi Tsushima, Daisuke Miura, Masami Takeuchi, Naoto Takahashi, Matsue Kosei
Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer science 112 (9) (2021)
Yuki Fujioka, Daisuke Sugiyama, Itaru Matsumura, Yosuke Minami, Masatomo Miura, Yoshiko Atsuta, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyoshi Nishikawa, Naoto Takahashi
Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers 13 (23) (2021)
Timothy P Hughes, Nelma Cristina D Clementino, Mikhail Fominykh, Jeffrey H Lipton, Anna G Turkina, Elena Beatriz Moiraghi, Franck E Nicolini, Naoto Takahashi, Tomasz Sacha, Dong-Wook Kim, Rafik Fellague-Chebra, Ranjan Tiwari, Catherine Bouard, Francois-Xavier Mahon
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia 35 (6) (2021)
Yumi Sasaki, Yong-Mei Guo, Tatsufumi Goto, Kumi Ubukawa, Ken Asanuma, Isuzu Kobayashi, Kenichi Sawada, Hideki Wakui, Naoto Takahashi
IL-6 Generated from Human Hematopoietic Stem and Progenitor Cells through TLR4 Signaling Promotes Emergency Granulopoiesis by Regulating Transcription Factor Expression. Journal of immunology (Baltimore, Md. : 1950) 207 (4) (2021)
Maiko Abumiya, Naoto Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura
Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance. Journal of clinical pharmacy and therapeutics 46 (1) (2020)
Sho Ikeda, Fumito Abe, Yuka Matsuda, Akihiro Kitadate, Naoto Takahashi, Hiroyuki Tagawa
Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma. Cancer science 111 (11) (2020)
Maiko Abumiya, Yumiko Akamine, Shiori Sato, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura
Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia. Journal of clinical pharmacy and therapeutics 46 (2) (2020)
Fumiko Ito, Masatomo Miura, Yuki Fujioka, Maiko Abumiya, Takahiro Kobayashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration. International journal of hematology 113 (1) (2020)
Masahide Takeda, Shigeharu Ueki, Yohei Yamamoto, Miho Nara, Mineyo Fukuchi, Katsutoshi Nakayama, Yasufumi Omori, Naoto Takahashi, Makoto Hirokawa
Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes. Asia Pacific allergy 10 (3) (2020)
Takaaki Ono, Naoto Takahashi, Masahiro Kizaki, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Tomoki Naoe, Itaru Matsumura
Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. Cancer science 111 (10) (2020)
Takaya Yamashita, Kazuhiro Ikegame, Fumiko Ito, Takahiro Kobayashi, Miho Nara, Naohito Fujishima, Akira Anbai, Takayuki Inoue, Katsuji Kaida, Hidenori Tanaka, Naoto Takahashi
Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. Bone marrow transplantation 54 (10) (2019)
Makoto Hirokawa, Naohito Fujishima, Masaru Togashi, Akiko Saga, Ayumi Omokawa, Tomoo Saga, Yuki Moritoki, Shigeharu Ueki, Naoto Takahashi, Kazutaka Kitaura, Ryuji Suzuki
High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/IGHJ4 gene in primary immune thrombocytopenia. Scientific reports 9 (1) (2019)
Takahiro Kobayashi, Masatomo Miura, Maiko Abumiya, Yumiko Akamine, Fumiko Ito, Naoto Takahashi
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. Medical oncology (Northwood, London, England) 36 (6) (2019)
Masahiro Kizaki, Naoto Takahashi, Noriyoshi Iriyama, Shinichiro Okamoto, Takaaki Ono, Noriko Usui, Koiti Inokuchi, Chiaki Nakaseko, Mineo Kurokawa, Masahiko Sumi, Fumihiko Nakamura, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Itaru Matsumura, Tomoki Naoe, null null
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. International journal of hematology 109 (4) (2019)
Shinsuke Noguchi, Chiaki Nakaseko, Kaichi Nishiwaki, Hitoshi Ogasawara, Kohshi Ohishi, Michihide Tokuhira, Masaaki Noguchi, Hideo Kimura, Hiroshi Handa, Kinuko Mitani, Masatomo Miura, Hisashi Wakita, Naoto Takahashi, null null
Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. International journal of hematology 108 (2) (2018)
Takahiro Kobayashi, Masatomo Miura, Maiko Abumiya, Takenori Niioka, Shuichi Kanno, Naoto Takahashi
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. Annals of hematology 97 (6) (2018)
Akiko Mita, Maiko Abumiya, Masatomo Miura, Takenori Niioka, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Experimental hematology & oncology 7 (2018)
Naoto Takahashi, Chiaki Nakaseko, Yukio Kobayashi, Koichi Miyamura, Chiho Ono, Yuichiro Koide, Yosuke Fujii, Kazunori Ohnishi
Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. International journal of hematology 106 (3) (2017)
Takashi Onaka, Naoto Takahashi, Masatomo Miura, Akihito Yonezawa
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant. Clinical case reports 5 (5) (2017)
Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yoshihiro Hatta, Yasuhiko Miyata, Shinichi Kobayashi, Kensuke Usuki, Itaru Matsumura, Yosuke Minami, Noriko Usui, Tetsuya Fukuda, Satoru Takada, Maho Ishikawa, Katsumichi Fujimaki, Hiroshi Gomyo, Osamu Sasaki, Kohshi Ohishi, Takaaki Miyake, Kiyotoshi Imai, Hitoshi Suzushima, Hideki Mitsui, Kazuto Togitani, Toru Kiguchi, Yoshiko Atsuta, Shigeki Ohtake, Kazunori Ohnishi, Yukio Kobayashi, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, null null
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. International journal of hematology 107 (2) (2017)